Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Mehr anzeigen
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – –...
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.178858 | -13.2487407407 | 1.35 | 1.45 | 1.03 | 3709631 | 1.18851057 | CS |
| 4 | -0.258858 | -18.101958042 | 1.43 | 1.7699 | 1.03 | 2250547 | 1.37073641 | CS |
| 12 | 0.421142 | 56.1522666667 | 0.75 | 2.43 | 0.695 | 5470925 | 1.4592107 | CS |
| 26 | -0.558858 | -32.3039306358 | 1.73 | 2.43 | 0.6603 | 3647546 | 1.33362797 | CS |
| 52 | -1.138858 | -49.3012121212 | 2.31 | 2.87 | 0.6603 | 2911000 | 1.62966643 | CS |
| 156 | -10.748858 | -90.1749832215 | 11.92 | 14.11 | 0.6603 | 2546162 | 3.71372419 | CS |
| 260 | -17.848858 | -93.8425762355 | 19.02 | 23.03 | 0.6603 | 1929094 | 6.53382481 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
